Asahi Kasei Corporation
http://www.asahi-kasei.co.jp/asahi/en/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Asahi Kasei Corporation
Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants
The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.
Organon Docks Into India’s Family Planning Program, Makes Early Gains
Organon's commercial director and lead for the South Asia region, Anjan Sen, discusses with Scrip the prospects of contraceptive Implanon NXT with its inclusion in India’s historic family planning program. The Merck spin-out is also on course to debut its Jada System this year, opening up new growth avenues as it disentangles and builds out operations in the region.
Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.
Petros Pharma Introduces AI As ACNU Option In Research For OTC Switch Of Stendra ED Drug
Petros is first to introduce an OTC switch labeling tool which could be the next obvious step hiding in plain sight – AI, which wasn’t noted in FDA’s ACNU proposal and hasn’t previously been linked to a switch.
Company Information
- Industry
- Diversified
- Medical Devices
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Advanced Circulatory Systems, Inc.
- Artisan Pharmaceuticals
- Asahi Kasei Holdings US, Inc.
- Asahi Kasei Pharma America Corp. (AKP America)
- Cardiac Science Corporation
- Golden Hour Data Systems, Inc.
- Kyma Medical Technologies, Ltd.
- Mobilize RRS LLC.
- TherOx, Inc.
- Veloxis Pharmaceuticals Inc.
- ZOLL Medical Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice